Dabur Pharma, a leading player in the domestic oncology segment, is busy finalising its marketing strategies for EU, the US and Australia.
The company is expecting five regulatory approvals in Europe for its generic cancer medicines. It has already received marketing approvals for two of its injectables carboplatin and paclitaxel and is in the process of getting approvals for another four products.
In Australia, Dabur expects to make an entry within 12 - 16 months with three of its generic products expecting marketing approvals.
Anand Burman, chairman, Dabur Pharma said the company was on the lookout for alliances in France and Spain to market its products in those countries.
"We are yet to finalise our strategies for Australia, he added. According to Burman, UK and Germany are the two markets where Dabur will have its own marketing set up. Dabur Oncology, the UK arm of Dabur Pharma, already has Britain.
The second and third phases of Dabur's green field manufacturing facility at Baddi, Himachal Pradesh is to be commissioned within two months.
The new facility, designed as per cGMP norms and conform to international regulatory requirement, is to be the global sourcing base for its products.
Dabur, the only Indian company to commercialise a nanotechnology platform-based drug delivery system in the country, is also looking at utlising the nanotech platform to deliver more such products.
"We would try to see if all our insoluble new chemical entities could be delivered using nanotechnology platform. We are trying to see if atleast 10 of our oncology products could be delivered effectively using nanotechnology platform."
Dr Rama Mukherjee, President, R & D, Dabur Research Foundation said. The company has already announced its plans for nanotechnology based delivery systems for docetaxel and etoposide.
